Immunic Unveils Promising Phase 2 Trial Results for Vidofludimus Calcium

Immunic, Inc. has released additional data from its Phase 2 CALLIPER trial, demonstrating promising results for its leading drug candidate, vidofludimus calcium, in treating progressive multiple sclerosis (PMS). Presented at the ACTRIMS Forum 2026, the findings highlight the drug's impact on key indicators of disease progression.

The trial data reveals significant reductions in both acute and chronic inflammatory activity as measured by MRI. Specifically, patients treated with vidofludimus calcium showed a decline in gadolinium-enhancing lesions from 16.4% to 0% over 120 weeks.

Additionally, the drug demonstrated strong antiviral effects, particularly against the Epstein-Barr virus (EBV), crucially linked to PMS. These findings indicate that vidofludimus calcium might address underlying disease mechanisms, potentially slowing PMS progression.